Olaparib (Lynparza)

Ingredients: Olaparib
Dosage Form: Oral tablets
Innovator’s Brand Name: Lynparza
Generic Brand Name: Olakin
Generic Manufacturer: Ziska Pharma

Indications:
Olaparib is indicated for the treatment of HER2‑negative metastatic breast cancer in patients with deleterious or suspected deleterious germline BRCA mutations confirmed by genetic testing, and as maintenance therapy following platinum‑based chemotherapy in patients with platinum‑sensitive recurrent high‑grade ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Dosage and Administration:
The recommended dose is 800 mg orally once daily, administered as 400 mg twice daily. If a dose is missed, resume dosing according to the original schedule. Adjust the dose as necessary under medical supervision to manage adverse reactions.

Adverse Reactions:
Common serious adverse reactions include anemia and thrombocytopenia; some patients may discontinue therapy as a result.

Storage:
Store in a cool, dry place below 30 °C, protected from light, and keep out of reach of children.

Package Insert (Prescribing Information):

Download Link